What does the evidence say about Vitamin K2 Supplementation Bone Density Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K2 Supplementation Bone Density Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - In the Global Burden of Disease 2019 analysis, low bone mineral density was associated with about 438,000 deaths and 166 million disability-adjusted life years, with large increases since 1990 (). [Zhang Zechen (2025); evidence level 1] - In a cross-sectional study of 900 Chinese adults, higher ucOC was associated with lower BMD at the spine, femoral neck, and hip, and with higher P1NP and β-CTX, indicating increased turnover (). [Zhang Zechen (2025); evidence level 1] - K2 deficiency has been linked to the “calcium paradox,” with insufficient skeletal deposition and increased vascular calcification (). [Zhang Zechen (2025); evidence level 1] - It is characterized by low bone mass and deterioration of bone microarchitecture. [Zhang Zechen (2025); evidence level 1] - 1 2 3 4 5 6 7 Osteopenia is a pre-pathological condition defined as the precursor of osteoporosis and characterized by reduced bone mineral density (BMD). [Nordio Maurizio (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.